The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| DICERNA PHARMACEUTICALS INC | COM | 253031108 | 136,275 | 8,930,237 | SH | SOLE | 8,930,237 | 0 | 0 | ||
| MARINUS PHARMACEUTICALS INC | COM | 56854Q101 | 39,775 | 3,977,453 | SH | SOLE | 3,977,453 | 0 | 0 | ||
| INFLARX NV | COM | N44821101 | 60,571 | 1,764,888 | SH | SOLE | 1,764,888 | 0 | 0 | ||
| SOLID BIOSCIENCES INC | COM | 83422E105 | 93,862 | 1,989,444 | SH | SOLE | 1,989,444 | 0 | 0 | ||
| APTINYX INC | COM | 03836N103 | 64,439 | 2,225,092 | SH | SOLE | 2,225,092 | 0 | 0 | ||
| REPLIMUNE GROUP INC | COM | 76029N106 | 45,707 | 2,838,968 | SH | SOLE | 2,838,968 | 0 | 0 | ||